Abstract
With the rapid advancement of technology, blood substitutes and alternate sources of therapeutic blood components are likely to become available, although not for a number of years. Within five to eight years, at least some plasma derivatives probably will be replaced by alternate sources using recombinant DNA technology; substitutes for RBCs and platelets will be much more difficult to develop. Availability of these products will have far-reaching effects on our health care system and it is probably not too soon to anticipate the effects and plan for the consequences.
| Original language | English |
|---|---|
| Pages (from-to) | 1-12 |
| Number of pages | 12 |
| Journal | Blood |
| Volume | 66 |
| Issue number | 1 |
| DOIs | |
| State | Published - 1985 |